Suppr超能文献

条件性KrasG12D等位基因的体细胞激活在体内导致无效的红细胞生成。

Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

作者信息

Braun Benjamin S, Archard Joehleen A, Van Ziffle Jessica A G, Tuveson David A, Jacks Tyler E, Shannon Kevin

机构信息

Department of Pediatrics, HSE-302, University of California-San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA.

出版信息

Blood. 2006 Sep 15;108(6):2041-4. doi: 10.1182/blood-2006-01-013490. Epub 2006 May 23.

Abstract

Somatic activation of a conditional targeted Kras(G12D) allele induces a fatal myeloproliferative disease in mice that closely models juvenile and chronic myelomonocytic leukemia. These mice consistently develop severe and progressive anemia despite adequate numbers of clonogenic erythroid progenitors in the bone marrow and expanded splenic hematopoiesis. Ineffective erythropoiesis is characterized by impaired differentiation. These results demonstrate that endogenous levels of oncogenic Ras have cell lineage-specific effects and support efforts to modulate Ras signaling for therapy of anemia in patients with myelodysplastic syndromes and myeloproliferative disorders.

摘要

条件性靶向Kras(G12D)等位基因的体细胞激活在小鼠中诱发一种致命的骨髓增殖性疾病,该疾病与青少年和慢性粒单核细胞白血病极为相似。尽管骨髓中克隆形成性红系祖细胞数量充足且脾造血功能增强,但这些小鼠仍持续出现严重且进行性的贫血。无效红细胞生成的特征是分化受损。这些结果表明,致癌性Ras的内源性水平具有细胞谱系特异性作用,并支持为治疗骨髓增生异常综合征和骨髓增殖性疾病患者的贫血而调节Ras信号传导的努力。

相似文献

1
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.
Blood. 2006 Sep 15;108(6):2041-4. doi: 10.1182/blood-2006-01-013490. Epub 2006 May 23.
2
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.
3
Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.
Leukemia. 2018 Apr;32(4):1023-1033. doi: 10.1038/leu.2017.326. Epub 2017 Nov 16.
5
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.
Nat Med. 2016 Mar;22(3):288-97. doi: 10.1038/nm.4047. Epub 2016 Feb 15.
6
Enhancing mitochondrial function in vivo rescues MDS-like anemia induced by pRb deficiency.
Exp Hematol. 2020 Aug;88:28-41. doi: 10.1016/j.exphem.2020.06.006. Epub 2020 Jul 3.
7
RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Clin Cancer Res. 2010 Apr 15;16(8):2246-56. doi: 10.1158/1078-0432.CCR-09-2112. Epub 2010 Apr 6.
8
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
J Clin Invest. 2013 Jan;123(1):335-9. doi: 10.1172/JCI63193. Epub 2012 Dec 10.
9
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602. doi: 10.1073/pnas.0307203101. Epub 2003 Dec 29.
10
Cdc42 critically regulates the balance between myelopoiesis and erythropoiesis.
Blood. 2007 Dec 1;110(12):3853-61. doi: 10.1182/blood-2007-03-079582. Epub 2007 Aug 16.

引用本文的文献

1
Noncoding Variants Connect Enhancer Dysregulation with Nuclear Receptor Signaling in Hematopoietic Malignancies.
Cancer Discov. 2020 May;10(5):724-745. doi: 10.1158/2159-8290.CD-19-1128. Epub 2020 Mar 18.
2
The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Genes Chromosomes Cancer. 2019 Dec;58(12):875-888. doi: 10.1002/gcc.22796. Epub 2019 Sep 3.
3
USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
Blood. 2018 Jul 26;132(4):423-434. doi: 10.1182/blood-2017-10-811760. Epub 2018 May 29.
4
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Leukemia. 2016 Jun;30(6):1335-43. doi: 10.1038/leu.2016.14. Epub 2016 Feb 12.
5
Emerging EPO and EPO receptor regulators and signal transducers.
Blood. 2015 Jun 4;125(23):3536-41. doi: 10.1182/blood-2014-11-575357. Epub 2015 Apr 17.
6
Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
Leukemia. 2015 May;29(5):1032-40. doi: 10.1038/leu.2014.315. Epub 2014 Nov 5.
7
Leukemogenic Ptpn11 allele causes defective erythropoiesis in mice.
PLoS One. 2014 Oct 7;9(10):e109682. doi: 10.1371/journal.pone.0109682. eCollection 2014.
8
HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia.
J Clin Invest. 2014 Mar;124(3):1158-67. doi: 10.1172/JCI71264.
9
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.
Am J Hematol. 2014 May;89(5):499-504. doi: 10.1002/ajh.23652. Epub 2014 Feb 10.
10
Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?
Haematologica. 2013 Jan;98(1):10-22. doi: 10.3324/haematol.2012.069385. Epub 2012 Oct 12.

本文引用的文献

1
Germline KRAS mutations cause Noonan syndrome.
Nat Genet. 2006 Mar;38(3):331-6. doi: 10.1038/ng1748. Epub 2006 Feb 12.
2
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
Pediatr Blood Cancer. 2006 May 1;46(5):579-85. doi: 10.1002/pbc.20644.
3
Focus on myeloproliferative diseases and myelodysplastic syndromes.
Cancer Cell. 2004 Dec;6(6):547-52. doi: 10.1016/j.ccr.2004.12.004.
4
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Nat Med. 2004 Aug;10(8):849-57. doi: 10.1038/nm1084. Epub 2004 Jul 25.
7
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.
Blood. 2004 Jun 1;103(11):4243-50. doi: 10.1182/blood-2003-08-2650. Epub 2004 Feb 24.
9
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602. doi: 10.1073/pnas.0307203101. Epub 2003 Dec 29.
10
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
Blood. 2004 Mar 15;103(6):2325-31. doi: 10.1182/blood-2003-09-3287. Epub 2003 Nov 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验